Drug intelligence / Profile preview

QX1206

Development stage: Phase 1
Lead developer: 1Globe Health Institute
Modality: Small Molecules
Administration: Oral

Overview

QX1206 is an investigational small molecule drug developed for the treatment of metabolic diseases, specifically type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD). It is currently in Phase 1 clinical trials. The precise mechanism of action for QX1206 has not been disclosed or remains unknown. The drug was initially developed by 1globe Health Institute LLC and is administered orally[1][2][3][4].

Beyond the preview

Go deeper on QX1206.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on QX1206.

Explore the full profile